載入...
Add-on perampanel in Lance–Adams syndrome
Perampanel (PER) is the first-in-class selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist that has been licensed and marketed as antiepileptic drug (AED) indicated for patients with partial-onset and primary generalized tonic–clonic seizures. A...
Na minha lista:
| 發表在: | Epilepsy Behav Case Rep |
|---|---|
| Main Authors: | , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Elsevier
2016
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4939387/ https://ncbi.nlm.nih.gov/pubmed/27437182 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebcr.2016.05.001 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|